Lubigut Capsule

Chronic Idiopathic Constipation: Lubigut is indicated for the treatment of chronic idiopathic constipation in adults.

Opioid-induced Constipation: Lubigut is indicated for the treatment of opioid-induced constipation in adults.

Irritable Bowel Syndrome with Constipation: Lubigut is the only FDA approved drug for the treatment of irritable bowel syndrome with constipation in women >18 years old.

Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum. Lubiprostone acts by specifically activating
ClC-2, which is a normal constituent of the apical membrane of the human intestine. By increasing intestinal fluid secretion, Lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with constipation. After administration, Lubiprostone and its metabolites are observed only on the apical (luminal) portion of the gastrointestinal epithelium. Additionally, activation of ClC-2 by Lubiprostone recovers mucosal barrier function via restoration of tight junction protein complexes. Lubiprostone relieves symptoms within 24 hours.

Chronic Idiopathic Constipation: Lubiprostone 24 mcg twice daily orally with food and water.

Opioid-induced Constipation: Lubiprostone 24 mcg twice daily orally with food and water.

Irritable Bowel Syndrome with Constipation: Lubiprostone 8 mcg should be taken twice daily orally with food and water.

Based upon the results of in vitro human microsome studies, there is low likelihood of drug-drug interactions. In vitro studies using human liver microsomes indicate that cytochrome P450 isoenzymes are not involved in the metabolism of Lubigut. Based on the available information, no protein binding–mediated drug interactions of clinical significance are anticipated.

Lubiprostone is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Nausea, vomiting, loose stools, dry mouth, stomach discomfort, headache, dizziness etc.

Pregnancy Category C. Lubiprostone should be used in pregnant mother if the potential benefits justifies the potential risk to the fetus. It is not known whether Lubiprostone is excreted in human milk.

Nausea: Patients taking Lubigut may experience nausea. If this occurs, concomitant administration of food with Lubigut may reduce symptoms of nausea.

Diarrhea: Lubigut should not be prescribed to patients that have severe diarrhea.

Bowel Obstruction: In patients with symptoms suggestive of mechanical gastrointestinal obstruction, confirm the absence of such an obstruction prior to initiating therapy with Lubigut.

Children & adolescents: Safety and effectiveness in children & adolescents has not been studied.

Geriatric use: Irritable Bowel Syndrome with Constipation: The safety and efficacy of Lubigut in the elderly (>65 years age) patients remains constant in both young and older patients.

Renal Impairment: Lubigut has not been studied in patients who have renal impairment.

Hepatic Impairment: Reduce the dosage in patients with moderate and severe hepatic impairment.

Adverse reactions due to overdose are nausea, diarrhea, vomiting, dizziness, headache & abdominal pain.

Other laxative preparations

Keep out of the reach of children. Store in a cool & dry place below 25°C, protect from light.